BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22790905)

  • 1. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.
    Gunnarsson C; Chen J; Rizzo JA; Ladapo JA; Lofland JH
    Dig Dis Sci; 2012 Dec; 57(12):3080-91. PubMed ID: 22790905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
    Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
    Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey.
    Gunnarsson C; Chen J; Rizzo JA; Ladapo JA; Naim A; Lofland JH
    J Dermatolog Treat; 2012 Aug; 23(4):240-54. PubMed ID: 21801089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
    Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
    Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.
    Sin AT; Damman JL; Ziring DA; Gleghorn EE; Garcia-Careaga MG; Gugig RR; Hunter AK; Burgis JC; Bass DM; Park KT
    Inflamm Bowel Dis; 2015 Jun; 21(6):1368-77. PubMed ID: 25839776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
    Vadstrup K; Alulis S; Borsi A; Elkjaer Stallknecht S; Nielsen A; Rikke Jørgensen T; Wennerström C; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Jan; 55(1):41-46. PubMed ID: 31960726
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
    Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
    J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Jackson B; Con D; Ma R; Gorelik A; Liew D; De Cruz P
    Scand J Gastroenterol; 2017 Aug; 52(8):851-856. PubMed ID: 28509590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Burden of Crohn's Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis-A Danish Register-Based Study From 2003-2015.
    Vadstrup K; Alulis S; Borsi A; Gustafsson N; Nielsen A; Wennerström ECM; Jørgensen TR; Qvist N; Munkholm P
    Inflamm Bowel Dis; 2020 Aug; 26(9):1377-1382. PubMed ID: 31693731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct medical cost of managing IBD patients: a Canadian population-based study.
    Bernstein CN; Longobardi T; Finlayson G; Blanchard JF
    Inflamm Bowel Dis; 2012 Aug; 18(8):1498-508. PubMed ID: 22109958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Care Cost for Children Newly Diagnosed With Inflammatory Bowel Disease.
    Fondell AW; Mosha MH; Frank CR; Brangi JM; Hyams JS
    Inflamm Bowel Dis; 2020 Mar; 26(4):635-640. PubMed ID: 31504513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
    Khalili H; Everhov ÅH; Halfvarson J; Ludvigsson JF; Askling J; Myrelid P; Söderling J; Olen O; Neovius M;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):655-668. PubMed ID: 32902894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data.
    Kotlarz H; Gunnarsson CL; Fang H; Rizzo JA
    Arthritis Rheum; 2009 Dec; 60(12):3546-53. PubMed ID: 19950287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
    Pillai N; Dusheiko M; Maillard MH; Rogler G; Brüngger B; Bähler C; Pittet VEH;
    J Crohns Colitis; 2019 May; 13(6):744-754. PubMed ID: 30916775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.